References – Abzena

Filter by year

Filter by topic

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin is a small (17 kDa) fungal ribonuclease produced by Aspergillus giganteus that functions by catalytically cleaving a single phosphodiester bond in the sarcin–ricin loop of the large ribosomal subunit, thus making the ribosome unrecognisable to elongation factors […]... Read more

Building a biologics capabilities network

This article explains how Abzena is building a biologics capabilities network through a slew of acquisitions. GEN May 15, 2016 (Vol. 36 No.10) http://www.genengnews.com/gen-articles/building-a-biologics-capabilities-network/5764/... Read more

The INNs and outs of antibody nonproprietary names

http://www.tandfonline.com/doi/full/10.1080/19420862.2015.1114320 Tim D. Jones, Paul J. Carter, Andreas Plückthun, Max Vásquez, Robert G.E. Holgate, Isidro Hötzel, Andrew G. Popplewell, Paul W.H.I. Parren, Markus Enzelberger, Hendrik J. Rademaker, Michael R. Clark, David C. Lowe, Bassil I. Dahiyat, Victoria Smith, John M. Lambert, Herren Wu, Mary Reilly, John S. Haurum, Stefan Dübel, James S. Huston, Thomas, Schirrmann, Richard A.J. Janssen, Martin […]... Read more

A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.

Carl I. Webster, Christine J. Bryson, Edward A. Cloake, Tim D. Jones, Mark J. Austin, Anette C. Karle, Sebastian Spindeldreher, David C. Lowe & Matthew P. Baker. mAbs, Volume 8, Issue 2, 2016 ABSTRACT The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of […]... Read more

Characterisation of a novel anti-CD52 antibody with improved efficacy and reduced immunogenicity

Holgate RGE, Weldon R, Jones TD, Baker MP (2015) Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity. PLoS ONE 10(9): e0138123. doi:10.1371/journal.pone.0138123 Abstract Anti-CD52 therapy has been shown to be effective in the treatment of a number of B cell malignancies, hematopoietic disorders and autoimmune diseases (including rheumatoid arthritis and multiple sclerosis); however the […]... Read more

In vitro and in vivo evaluation of cysteine rebridged trastuzumab–MMAE antibody drug conjugates with defined drug-to-antibody ratios

Penny Bryant, Martin Pabst, George Badescu, Matthew Bird, William McDowell, Estera Jamieson, Julia Swierkosz, Kosma Jurlewicz, Rita Tommasi, Korinna Henseleit, XiaoBo Sheng, Nicolas Camper, Anais Manin, Katarzyna Kozakowska, Karolina Peciak, Emmanuelle Laurine, Ruslan Grygorash, Andrew Kyle, David Morris, Vimal Parekh, Amrita Abhilash, Ji-won Choi, Jeff Edwards, Mark Frigerio, Matthew P. Baker, and Antony Godwin Abstract […]... Read more

Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics

Maryam Ahmadi, Christine J. Bryson, Edward A. Cloake, Katie Welch, Vasco Filipe, Stefan Romeijn, Andrea Hawe, Wim Jiskoot, Matthew P. Baker, Mark H. Fogg. Pharmaceutical Research, An Official Journal of the American Association of Pharmaceutical Scientists, ISSN 0724-8741, Pharm Res, DOI 10.1007/s11095-014-1541-x Abstract PURPOSE: Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically […]... Read more

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity This article discusses how early removal of T-cell epitopes reduces risk of adverse immune responses in patients and how technologies such as Composite Human Antibodies can achieve this. Ji-won Choi. GEN; March 2015.... Read more

Conjugation of PolyPEG to Interferon Alpha Extends Serum Half-Life while Maintaining Low Viscosity of the Conjugate

B. Podobnik, B. Helk, V. Smilović, Š. Škrajnar, K. Fidler, S. Jevševar, A. Godwin, and P. Williams. Bioconjugate Chem., 2015, 26 (3), pp 452–459 Abstract The covalent attachment of poly(ethylene glycol) (PEG) to therapeutic proteins is a commonly used approach for extending in vivo half-lives. A potential limitation of this PEGylation strategy is the adverse effect […]... Read more

Technology Advances Enable Creation of Better ADCs

Technology Advances Enable Creation of Better ADCs Waterman.  BioProcess International. 2014; 12(9)s: 37-40... Read more

Interested in our services? Get In Touch